Ann: Investor Webinar Presentation, page-5

I hope to see holders tune in and ask the important questions.I personally will ask the below if given the opportunity:1) Why is revenue uptick been sluggish for a proven product, with the company having soo many regulatory approvals and market education going on; What is the real barrier here ? Is it cost ? or something more pressing ?2) Is there an update on CR ? The company is playing it too close to the chest with liquidity - this is clearly hurting SP - is there a plan for an institutional placement ?3) Understand the focus on China - however, India is another high populous nation - why are we not seeing revenue uptick over there ? It's not even 10 - 20K in revenue out of India - why is that ?